Update publication information. (1) A N-glycopeptide method based on 18O/16O C-terminal labelling to obtain comparisons of serum from patients with HBV-related hepatocellular carcinoma (HCC-O18 labelling) and HBV-related liver cirrhosis (LC-O16 labelling) (2) MRM verification of N-glycopeptide alterations